First safety check: new drug tested in people with kidney problems
NCT ID NCT07032272
Summary
This early-stage study aimed to understand how a new drug called remibrutinib is processed by the body in people with severe kidney impairment. It involved 16 participants—half with poor kidney function and half healthy—to measure drug levels in their blood and urine. The goal was to gather data to help determine safe dosing for future patients with kidney problems.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE AND CHRONIC INFLAMMATORY DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Pharmacology of Miami LLC
Miami, Florida, 33014-3616, United States
-
Genesis Clinical Research
Tampa, Florida, 33614, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States
-
Panax Clinical Research
Miami Lakes, Florida, 33014, United States
Conditions
Explore the condition pages connected to this study.